NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $18.25 +0.82 (+4.70%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Silence Therapeutics alerts: Email Address About Silence Therapeutics Stock (NASDAQ:SLN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silence Therapeutics alerts:Sign Up Key Stats Today's Range$17.36▼$18.3650-Day Range$15.53▼$21.7452-Week Range$6.15▼$27.72Volume301,753 shsAverage Volume207,237 shsMarket Capitalization$546.22 millionP/E RatioN/ADividend YieldN/APrice Target$57.20Consensus RatingBuy Company OverviewSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More… Don’t wait for FDA approval (Ad)Don’t let Wall Street fool you. AI is not the only hot sector in the market. Biotech is on fire as well.And I’ll tell you all about them in this video. Silence Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreSLN MarketRank™: Silence Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 442nd out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Silence Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -15.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -15.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 25.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Silence Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.98% of the outstanding shares of Silence Therapeutics have been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently increased by 15.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.98% of the outstanding shares of Silence Therapeutics have been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently increased by 15.55%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.08 News SentimentSilence Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Silence Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Stock News HeadlinesSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSeptember 27 at 8:26 AM | americanbankingnews.comSilence: Additional siRNA Drug Data Leads To Next Stages Of DevelopmentSeptember 5, 2024 | seekingalpha.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.September 27, 2024 | Paradigm Press (Ad)Silence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesAugust 27, 2024 | businesswire.comBuy Rating Affirmed for Silence Therapeutics Amid Strong Pipeline Progress and Strategic PartnershipsAugust 16, 2024 | markets.businessinsider.comAnalyst Expectations For Silence Therapeutics's FutureAugust 16, 2024 | benzinga.comAnalysts Conflicted on These Healthcare Names: MiNK Therapeutics (INKT), Silence Therapeutics (SLN) and Mersana Therapeutics (MRSN)August 16, 2024 | markets.businessinsider.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024August 15, 2024 | investorplace.comSee More Headlines SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $17.37 on January 1st, 2024. Since then, SLN stock has increased by 5.1% and is now trading at $18.25. View the best growth stocks for 2024 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) issued its quarterly earnings data on Thursday, August, 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.10. The company earned $0.76 million during the quarter, compared to analysts' expectations of $11.28 million. Silence Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 222.44%. Who are Silence Therapeutics' major shareholders? Top institutional shareholders of Silence Therapeutics include Lombard Odier Asset Management USA Corp (8.04%), Millennium Management LLC (2.62%), First Turn Management LLC (1.80%) and SG Americas Securities LLC (1.15%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/15/2024Today9/27/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees100Year Founded1999Price Target and Rating Average Stock Price Target$57.20 High Stock Price Target$75.00 Low Stock Price Target$40.00 Potential Upside/Downside+213.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,820,000.00 Net Margins-222.44% Pretax Margin-258.08% Return on Equity-58.28% Return on Assets-27.77% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual Sales$31.55 million Price / Sales17.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book25.70Miscellaneous Outstanding Shares29,930,000Free Float29,045,000Market Cap$546.22 million OptionableNot Optionable Beta1.29 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:SLN) was last updated on 9/27/2024 by MarketBeat.com Staff From Our Partners10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential election...Chaikin Analytics | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.